Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism.
Colonic Neoplasms
/ genetics
Creatine
/ genetics
Energy Metabolism
/ genetics
Fructose-Bisphosphate Aldolase
/ genetics
Glucose
/ metabolism
Glucose Transport Proteins, Facilitative
/ genetics
Glycolysis
/ genetics
HCT116 Cells
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
/ genetics
Spheroids, Cellular
/ metabolism
Tumor Hypoxia
/ genetics
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
30
03
2018
revised:
28
01
2019
accepted:
13
03
2019
pubmed:
20
3
2019
medline:
2
5
2020
entrez:
20
3
2019
Statut:
ppublish
Résumé
Hypoxia-inducible factor 1α is a key regulator of the hypoxia response in normal and cancer tissues. It is well recognized to regulate glycolysis and is a target for therapy. However, how tumor cells adapt to grow in the absence of HIF1α is poorly understood and an important concept to understand for developing targeted therapies is the flexibility of the metabolic response to hypoxia via alternative pathways. We analyzed pathways that allow cells to survive hypoxic stress in the absence of HIF1α, using the HCT116 colon cancer cell line with deleted HIF1α versus control. Spheroids were used to provide a 3D model of metabolic gradients. We conducted a metabolomic, transcriptomic, and proteomic analysis and integrated the results. These showed surprisingly that in three-dimensional growth, a key regulatory step of glycolysis is Aldolase A rather than phosphofructokinase. Furthermore, glucose uptake could be maintained in hypoxia through upregulation of GLUT14, not previously recognized in this role. Finally, there was a marked adaptation and change of phosphocreatine energy pathways, which made the cells susceptible to inhibition of creatine metabolism in hypoxic conditions. Overall, our studies show a complex adaptation to hypoxia that can bypass HIF1α, but it is targetable and it provides new insight into the key metabolic pathways involved in cancer growth. IMPLICATIONS: Under hypoxia and HIF1 blockade, cancer cells adapt their energy metabolism via upregulation of the GLUT14 glucose transporter and creatine metabolism providing new avenues for drug targeting.
Identifiants
pubmed: 30885992
pii: 1541-7786.MCR-18-0315
doi: 10.1158/1541-7786.MCR-18-0315
doi:
Substances chimiques
Glucose Transport Proteins, Facilitative
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
SLC2A14 protein, human
0
Fructose-Bisphosphate Aldolase
EC 4.1.2.13
Glucose
IY9XDZ35W2
Creatine
MU72812GK0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1531-1544Subventions
Organisme : Medical Research Council
ID : MR/P010334/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/12/34040
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/8/30266
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C602/A18974
Pays : United Kingdom
Informations de copyright
©2019 American Association for Cancer Research.